These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Evaluation of an antacid-antisecretory drug. GUTH PH; ALLEN R Am J Gastroenterol; 1959 Sep; 32():360-9. PubMed ID: 13830442 [No Abstract] [Full Text] [Related]
26. [The drug prophylaxis of peptic ulcer exacerbations]. Grigor'ev PIa; Iakovenko EP; Agafonova NA; Prianishnikova AS; Soluianova IP; Iakovenko AV; Vasil'ev IV; Agrba VZ; Stepanov AV; Kolodkin AM Ter Arkh; 1995; 67(2):26-9. PubMed ID: 7725253 [TBL] [Abstract][Full Text] [Related]
27. Anti-ulcer drugs in antisecretory doses for "cytoprotection" in arthritic patients? Londong W Klin Wochenschr; 1986; 64 Suppl 7():32-4. PubMed ID: 2882050 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic failure and relapse in peptic ulcer. Ponce J; Rodrigo JM Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():123-30. PubMed ID: 2657282 [TBL] [Abstract][Full Text] [Related]
29. [The search for anti-ulcer agents at IDR]. AndrĂ¡si F Acta Pharm Hung; 2001; 71(1):40-3. PubMed ID: 11769095 [TBL] [Abstract][Full Text] [Related]
31. Misoprostol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease. Monk JP; Clissold SP Drugs; 1987 Jan; 33(1):1-30. PubMed ID: 3102205 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the dyspeptic patient: a cost-utility study. Ebell MH; Warbasse L; Brenner C J Fam Pract; 1997 Jun; 44(6):545-55. PubMed ID: 9191627 [TBL] [Abstract][Full Text] [Related]
33. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate. Bianchi Porro G; Parente F J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753 [TBL] [Abstract][Full Text] [Related]
34. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111 [TBL] [Abstract][Full Text] [Related]
35. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Clissold SP; Campoli-Richards DM Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658 [TBL] [Abstract][Full Text] [Related]
36. [Eradication of Helicobacter pylori and use of antisecretory drugs--a population based study]. Lassen AT; Hallas J; Schaffalitzky de Muckadell OB Ugeskr Laeger; 2004 Sep; 166(39):3405-7. PubMed ID: 15515395 [No Abstract] [Full Text] [Related]
37. [Side effects of current anti-Helicobacter therapy]. Maev IV; V'iuchnova ES; Petrova EG Klin Med (Mosk); 2002; 80(6):7-12. PubMed ID: 12138810 [TBL] [Abstract][Full Text] [Related]
38. [Chronotherapy approaches in the treatment of gastroduodenal ulcer]. Maev IV; V'iuchnova ES; Dicheva DT; Lebedeva EG Klin Med (Mosk); 2002; 80(3):46-9. PubMed ID: 11980160 [TBL] [Abstract][Full Text] [Related]
39. [Role of antisecretory therapy in prophylaxis and treatment of postoperative stress ulcers of the digestive tract in patients with malignant tumors using preparation omez]. Kobezkaia OG; Koreniuk DE; Obraztsov IG; Terzi IuN Klin Khir; 2006 Oct; (10):10-3. PubMed ID: 17269398 [TBL] [Abstract][Full Text] [Related]
40. [Anticholinergics and cytoprotectants in gastroduodenal ulcer]. Bernardi P; Fidanza F; Mancini L; Pace V Riv Eur Sci Med Farmacol; 1993; 15(2):99-105. PubMed ID: 8171220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]